{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:39:45Z","timestamp":1790005185517,"version":"4.0.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.xphs.2019.04.019","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T23:47:28Z","timestamp":1556581648000},"page":"3443-3456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions"],"prefix":"10.1016","volume":"108","author":[{"given":"Taleah","family":"Farasyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Neuhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khondoker","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Kanyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TuKiet T.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2019.04.019_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-14541-4_1","article-title":"Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms","volume":"201","author":"K\u00f6nig","year":"2011","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2019.04.019_bib2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/jpet.102.041921","article-title":"Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A","volume":"304","author":"Shitara","year":"2003","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"8","key":"10.1016\/j.xphs.2019.04.019_bib3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 7","key":"10.1016\/j.xphs.2019.04.019_bib4","first-page":"S59","article-title":"Comparing various in\u00a0vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1","volume":"56","author":"Vaidyanathan","year":"2016","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2019.04.019_bib5","series-title":"In\u00a0Vitro Metabolism and Transporter Mediated Drug-Drug Interaction Studies Guidance for Industry","year":"2017"},{"key":"10.1016\/j.xphs.2019.04.019_bib6","series-title":"Guideline on the Investigation of Drug Interactions","year":"2012"},{"issue":"2","key":"10.1016\/j.xphs.2019.04.019_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.114.059105","article-title":"Investigation of the impact of substrate selection on in\u00a0vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions","volume":"43","author":"Izumi","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.xphs.2019.04.019_bib8","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.xphs.2017.03.022","article-title":"Pretreatment with rifampicin and tyrosine kinase inhibitor dasatinib potentiates the inhibitory effects toward OATP1B1- and OATP1B3-mediated transport","volume":"106","author":"Pahwa","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2019.04.019_bib9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s11095-012-0918-y","article-title":"Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential","volume":"30","author":"Gertz","year":"2013","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2019.04.019_bib10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cpt.391","article-title":"Quantitative analyses of hepatic OATP-mediated interactions between statins and inhibitors using PBPK modeling with a parameter optimization method","volume":"100","author":"Yoshikado","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2019.04.019_bib11","series-title":"Rapamune (sirolimus) Package Insert","year":"2000"},{"key":"10.1016\/j.xphs.2019.04.019_bib12","series-title":"Zortress\u00ae (everolimus) tablets prescribing information","year":"2010"},{"issue":"11","key":"10.1016\/j.xphs.2019.04.019_bib13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.xphs.2019.04.019_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Reviews Drug Discovery"},{"issue":"1","key":"10.1016\/j.xphs.2019.04.019_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.01.005","article-title":"mTOR inhibitors in cancer therapy","volume":"319","author":"Zaytseva","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.xphs.2019.04.019_bib16","series-title":"Afinitor\u00ae (everolimus) tablets prescribing information","year":"2009"},{"key":"10.1016\/j.xphs.2019.04.019_bib17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/ndt\/14.3.648","article-title":"Cardiovascular morbidity and risk factors in renal transplant patients","volume":"14","author":"Aakhus","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.xphs.2019.04.019_bib18","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1681\/ASN.2008090925","article-title":"Statin use prolongs patient survival after renal transplantation","volume":"19","author":"Ritz","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.xphs.2019.04.019_bib19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1464-410X.2012.11720.x","article-title":"Phase II study of everolimus in metastatic urothelial cancer","volume":"112","author":"Milowsky","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.xphs.2019.04.019_bib20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/1752-1947-8-386","article-title":"Everolimus in acute kidney injury in a patient with breast cancer: a case report","volume":"8","author":"Donders","year":"2014","journal-title":"J\u00a0Med Case Rep"},{"issue":"11","key":"10.1016\/j.xphs.2019.04.019_bib21","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1097\/01.TP.0000085287.03333.FC","article-title":"Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient","volume":"76","author":"Barshes","year":"2003","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.xphs.2019.04.019_bib22","first-page":"152","article-title":"Severe rhabdomyolysis associated with concurrent use of simvastatin and sirolimus after cisplatin-based chemotherapy in a kidney transplant recipient","volume":"12","author":"Hong","year":"2014","journal-title":"Exp Clin Transplant"},{"issue":"6","key":"10.1016\/j.xphs.2019.04.019_bib23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.xphs.2019.04.019_bib24","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3109\/00498254.2011.573882","article-title":"Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters","volume":"41","author":"Picard","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.xphs.2019.04.019_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1097-2765(02)00636-6","article-title":"Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control","volume":"10","author":"Loewith","year":"2002","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.xphs.2019.04.019_bib26","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/1535-7163.MCT-10-1099","article-title":"Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin","volume":"10","author":"Bhagwat","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.xphs.2019.04.019_bib27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.bbrc.2014.06.081","article-title":"The novel mTORC1\/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells","volume":"450","author":"Lou","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.xphs.2019.04.019_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1471-2105-7-163","article-title":"PPSP: prediction of PK-specific phosphorylation site with Bayesian decision theory","volume":"7","author":"Xue","year":"2006","journal-title":"BMC Bioinformatics"},{"issue":"11","key":"10.1016\/j.xphs.2019.04.019_bib29","doi-asserted-by":"crossref","first-page":"e0186924","DOI":"10.1371\/journal.pone.0186924","article-title":"Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner","volume":"12","author":"Alam","year":"2017","journal-title":"PLoS One"},{"issue":"30","key":"10.1016\/j.xphs.2019.04.019_bib30","doi-asserted-by":"crossref","first-page":"23161","DOI":"10.1074\/jbc.M001448200","article-title":"Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide","volume":"275","author":"K\u00f6nig","year":"2000","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.xphs.2019.04.019_bib31","doi-asserted-by":"crossref","first-page":"G156","DOI":"10.1152\/ajpgi.2000.278.1.G156","article-title":"A\u00a0novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane","volume":"278","author":"Konig","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"10.1016\/j.xphs.2019.04.019_bib32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1021\/acs.molpharmaceut.5b00763","article-title":"Downregulation of organic anion transporting polypeptide (OATP) 1B1 transport function by lysosomotropic drug chloroquine: implication in OATP-mediated drug-drug interactions","volume":"13","author":"Alam","year":"2016","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2019.04.019_bib33","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1124\/dmd.114.056945","article-title":"Novel mechanism of impaired function of organic anion-transporting polypeptide 1B3 in human hepatocytes: post-translational regulation of OATP1B3 by protein kinase C activation","volume":"42","author":"Powell","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.xphs.2019.04.019_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/jpet.104.068056","article-title":"Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans","volume":"311","author":"Hirano","year":"2004","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/j.xphs.2019.04.019_bib35","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2019.04.019_bib36","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1172\/JCI101676","article-title":"The estimation of hepatic blood flow in man","volume":"24","author":"Bradley","year":"1945","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.xphs.2019.04.019_bib37","series-title":"Center for Drug Evaluation and Research Office of Clinical Pharmacology","article-title":"Everolimus clinical pharmacology and biopharmaceutics review","year":"2009"},{"key":"10.1016\/j.xphs.2019.04.019_bib38","series-title":"Package Insert","year":"2009"},{"key":"10.1016\/j.xphs.2019.04.019_bib39","series-title":"ACD\/Structure Elucidator","year":"2017"},{"issue":"10","key":"10.1016\/j.xphs.2019.04.019_bib40","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/rcm.4022","article-title":"Ultra-performance hydrophilic interaction liquid chromatography\/tandem mass spectrometry for the determination of everolimus in mouse plasma","volume":"23","author":"Hsieh","year":"2009","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"1","key":"10.1016\/j.xphs.2019.04.019_bib41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.112969","article-title":"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine","volume":"69","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.xphs.2019.04.019_bib42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1067\/mcp.2001.118022","article-title":"Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications","volume":"70","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.xphs.2019.04.019_bib43","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/jps.24495","article-title":"Use of a physiologically based pharmacokinetic model for quantitative prediction of drug-drug interactions via CYP3A4 and estimation of the intestinal availability of CYP3A4 substrates","volume":"104","author":"Mano","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2019.04.019_bib44","series-title":"Afinitor (Everolimus) Summary of Product Characteristics","year":"2014"},{"issue":"7","key":"10.1016\/j.xphs.2019.04.019_bib45","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s11095-012-0724-6","article-title":"Drug-drug interaction potential of marketed oncology drugs: in\u00a0vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction","volume":"29","author":"Kenny","year":"2012","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2019.04.019_bib46","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/jcph.7","article-title":"A\u00a0phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects","volume":"53","author":"Urva","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2019.04.019_bib47","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1038\/psp.2013.33","article-title":"Development of a physiologically-based pharmacokinetic model for sirolimus: predicting bioavailability based on intestinal CYP3A content","volume":"2","author":"Emoto","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2019.04.019_bib48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","article-title":"Population-based mechanistic prediction of oral drug absorption","volume":"11","author":"Jamei","year":"2009","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.xphs.2019.04.019_bib49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/bdd.2072","article-title":"Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon","volume":"38","author":"Pade","year":"2017","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.xphs.2019.04.019_bib50","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1023\/A:1011940108365","article-title":"In\u00a0vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin","volume":"15","author":"Crowe","year":"1998","journal-title":"Pharm Res"},{"issue":"7","key":"10.1016\/j.xphs.2019.04.019_bib51","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/dmd.31.7.938","article-title":"In\u00a0vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5","volume":"31","author":"Patki","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.xphs.2019.04.019_bib52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0090-9556(24)15273-7","article-title":"Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver","volume":"27","author":"Jacobsen","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.xphs.2019.04.019_bib53","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/jpet.103.060194","article-title":"Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human","volume":"308","author":"Nozawa","year":"2004","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/j.xphs.2019.04.019_bib54","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s11095-010-0216-5","article-title":"Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide","volume":"27","author":"Shirasaka","year":"2010","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2019.04.019_bib55","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/jpet.108.146647","article-title":"Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans","volume":"328","author":"Watanabe","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.xphs.2019.04.019_bib56","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/jps.22586","article-title":"Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and\/or P-glycoprotein","volume":"100","author":"Shirasaka","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2019.04.019_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pharmthera.2006.03.003","article-title":"Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions","volume":"112","author":"Shitara","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.xphs.2019.04.019_bib58","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1124\/dmd.109.027367","article-title":"Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients","volume":"37","author":"Wojtal","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.xphs.2019.04.019_bib59","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1124\/dmd.106.013342","article-title":"Regional distribution of solute carrier mRNA expression along the human intestinal tract","volume":"35","author":"Meier","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.xphs.2019.04.019_bib60","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1124\/dmd.107.014902","article-title":"Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines","volume":"35","author":"Hilgendorf","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2019.04.019_bib61","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpba.2013.07.031","article-title":"LC-MS\/MS-based quantification of clinically relevant intestinal uptake and efflux transporter proteins","volume":"85","author":"Groer","year":"2013","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"8","key":"10.1016\/j.xphs.2019.04.019_bib62","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1021\/acs.molpharmaceut.6b00085","article-title":"Quantitative atlas of cytochrome P450, UDP-glucuronosyltransferase, and transporter proteins in jejunum of morbidly obese subjects","volume":"13","author":"Miyauchi","year":"2016","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2019.04.019_bib63","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1021\/mp500330y","article-title":"Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine","volume":"11","author":"Drozdzik","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2019.04.019_bib64","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/j.1552-4604.1997.tb04318.x","article-title":"Pharmacokinetics of sirolimus in stable renal transplant patients after multiple dose administration","volume":"37","author":"Zimmerman","year":"1997","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2019.04.019_bib65","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00007691-200010000-00006","article-title":"Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers","volume":"22","author":"Brattstrom","year":"2000","journal-title":"Ther Drug Monit"},{"issue":"18","key":"10.1016\/j.xphs.2019.04.019_bib66","doi-asserted-by":"crossref","first-page":"15461","DOI":"10.1074\/jbc.C200665200","article-title":"The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif","volume":"278","author":"Nojima","year":"2003","journal-title":"J\u00a0Biol Chem"},{"issue":"9","key":"10.1016\/j.xphs.2019.04.019_bib67","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.cellsig.2013.05.001","article-title":"mTOR complex 2 mediates Akt phosphorylation that requires PKCepsilon in adult cardiac muscle cells","volume":"25","author":"Moschella","year":"2013","journal-title":"Cell Signal"},{"issue":"4","key":"10.1016\/j.xphs.2019.04.019_bib68","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-08-0668","article-title":"Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K\/mTOR inhibition","volume":"8","author":"Breuleux","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.xphs.2019.04.019_bib69","series-title":"search Mdh","article-title":"Scoring: mascot probability based scoring","year":"2016"},{"issue":"11","key":"10.1016\/j.xphs.2019.04.019_bib70","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.jasms.2010.06.006","article-title":"Accurate mass measurement: terminology and treatment of data","volume":"21","author":"Brenton","year":"2010","journal-title":"J\u00a0Am Soc Mass Spectrom"},{"key":"10.1016\/j.xphs.2019.04.019_bib71","series-title":"Scoring: Mascot Probability Based Scoring. Mascot Database Help Search","year":"2016"},{"issue":"12","key":"10.1016\/j.xphs.2019.04.019_bib72","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1021\/pr200611n","article-title":"Universal and confident phosphorylation site localization using phosphoRS","volume":"10","author":"Taus","year":"2011","journal-title":"J\u00a0Proteome Res"},{"issue":"12","key":"10.1016\/j.xphs.2019.04.019_bib73","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1097\/01.TP.0000443225.66960.7e","article-title":"More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients","volume":"97","author":"Robertsen","year":"2014","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.xphs.2019.04.019_bib74","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0149-2918(03)80214-X","article-title":"A\u00a0double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in HealthyVolunteers","volume":"23","author":"Martin","year":"2003","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.xphs.2019.04.019_bib75","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.transproceed.2009.02.019","article-title":"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient","volume":"41","author":"Dopazo","year":"2009","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.xphs.2019.04.019_bib76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ndt\/gfq157","article-title":"Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and rapamycin in a renal transplant recipient","volume":"25","author":"Basic-Jukic","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.xphs.2019.04.019_bib77","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1023\/A:1011077109233","article-title":"Inhibition of in\u00a0vitro metabolism of simvastatin by itraconazole in humans and prediction of in\u00a0vivo drug-drug interactions","volume":"18","author":"Ishigam","year":"2001","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2019.04.019_bib78","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0090-9556(24)14919-7","article-title":"The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions","volume":"27","author":"Fischer","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.xphs.2019.04.019_bib79","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000139380","article-title":"Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine","volume":"52","author":"Lampen","year":"1996","journal-title":"Pharmacology"},{"issue":"4","key":"10.1016\/j.xphs.2019.04.019_bib80","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.DMPK-11-RG-096","article-title":"Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake","volume":"27","author":"Shitara","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.xphs.2019.04.019_bib81","first-page":"166","article-title":"TMbase - A database of membrane spanning proteins segments","volume":"374","author":"Hofmann","year":"1993","journal-title":"Biol Chem Hoppe-Seyler"},{"issue":"2","key":"10.1016\/j.xphs.2019.04.019_bib82","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ddstr.2009.12.001","article-title":"mTOR mediated anti-cancer drug discovery","volume":"6","author":"Liu","year":"2009","journal-title":"Drug Discov Today Ther Strateg"},{"key":"10.1016\/j.xphs.2019.04.019_bib83","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pharmthera.2017.02.042","article-title":"Preincubation-dependent and long-lasting inhibition of organic anion transporting polypeptide (OATP) and its impact on drug-drug interactions","volume":"177","author":"Shitara","year":"2017","journal-title":"Pharmacol Ther"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354919302527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354919302527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:26:38Z","timestamp":1758360398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354919302527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0022354919302527"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2019.04.019","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2019.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}